Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
PHASE1Active, not recruitingINTERVENTIONAL
Enrollment
114
Participants
Timeline
Start Date
July 20, 2023
Primary Completion Date
January 22, 2024
Study Completion Date
September 30, 2024
Conditions
Healthy Men
Interventions
DRUG
Pertuzumab
i.v.
DRUG
Perjeta®
i.v.
Trial Locations (1)
Unknown
"Central Clinical Hospital RZD-Medicina", Moscow
All Listed Sponsors
lead
Mabscale, LLC
INDUSTRY
NCT05825781 - Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man | Biotech Hunter | Biotech Hunter